Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial

BACKGROUND: In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once‐weekly resulted in a nonsignificant reduction in major adverse cardiovascular events (MACEs) and a nominal 14% reduction in all‐cause mortality in 14 752 patients with type 2 diabetes mellitus (T2DM) with an...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Am Heart Assoc
Κύριοι συγγραφείς: Mentz, Robert J., Bethel, M. Angelyn, Merrill, Peter, Lokhnygina, Yuliya, Buse, John B., Chan, Juliana C., Felício, João S., Goodman, Shaun G., Choi, Jasmine, Gustavson, Stephanie M., Iqbal, Nayyar, Lopes, Renato D., Maggioni, Aldo P., Öhman, Peter, Pagidipati, Neha J., Poulter, Neil R., Ramachandran, Ambady, Reicher, Barry, Holman, Rury R., Hernandez, Adrian F.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2018
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6404902/
https://ncbi.nlm.nih.gov/pubmed/30371301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.009304
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια